We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App




D-Dimer and Thrombosis Risk in Adult Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 07 Sep 2022

D-dimer is a marker of fibrinolysis harkening the presence of or risk for thrombosis, and it has been found to be a powerful predictor of thrombosis in solid cancers and acute myeloid leukemia (AML). More...

Patients with acute lymphoblastic leukemia (ALL) are at increased risk of thrombotic and/or bleeding events during early chemotherapy, especially when receiving asparaginase. Rates of venous thromboembolism (VTE) in ALL vary across studies, ranging from 1% to 36%, with the majority of studies reporting rates in the 5% to 20% range over a 1- to 3-year follow-up period.

A team of medical scientists led by The University of Chicago (Chicago, IL, USA) team identified 61 consecutive adult patients with newly diagnosed ALL from a single center between January 2008 and March 2020. They gathered demographic characteristics, treatment regimens, initial biomarkers including D-dimer, and assessing occurrence of venous or arterial thrombosis and bleeding in the first 100 days after diagnosis (index). The median age overall was 36 years (range, 18-84 years), with 52% female.

The D-dimer assay is ordered routinely at diagnosis of ALL at The University of Chicago Medical Center as a plasma assay and performed using photometric immunoassay analysis on a STA R Max analyzer (Diagnostica Stago, Inc, Parsippany, NJ, USA) within six hours of blood draw. Patients were stratified into two groups according to index D-dimer level using a cutoff of ≥4 µg/mL fibrinogen equivalent units (FEU) (high) and <4 µg/mL (low to moderate) based on previous work examining D-dimer and thrombosis in AML and the cutoff used in the disseminated intravascular coagulation (DIC) score.

The investigators reported that in the study cohort of patients with ALL, of whom 17 (28%) had high (≥4 µg/mL FEU) D-dimer levels at index, and 44 (72%) had low to moderate (<4 µg/mL FEU) index D-dimer levels. The 100-day cumulative incidence (95% confidence interval [CI]) of venous or arterial thrombosis in patients with high D-dimer (≥4 µg/mL) was 52.9% (95% CI, 26.4-73.8) compared with 13.8% (95% CI, 5.5-25.7) in patients with low to moderate D-dimer (<4 µg/mL), corresponding with a hazard ratio of 5.04 (95% CI, 1.79-14.22). When testing for potential confounders in a series of bivariate logistic regression models, the association between D-dimer and thrombosis remained after adjusting for body mass index, age, sex, asparaginase treatment, disseminated intravascular coagulation score, initial platelet level, and ALL phenotype.

The authors concluded that D-dimer levels at ALL diagnosis were associated with venous or arterial thrombosis at 100 days. Future studies should include D-dimer collated with other known risk factors to build a risk assessment model for thrombosis in patients newly diagnosed with ALL. The study was published on September 1, 2022 in the journal Blood Advances.

Related Links:
The University of Chicago 
Diagnostica Stago 


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Glucose Tolerance Test
NERL Trutol
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.